IPO Overview
Hong Kong-based medical equipment procurer Brand Meditech files and sets terms for a $7 million US IPO
Brand Meditech, a Hong Kong-based procurer of medical devices and software to distributors, filed on Thursday with the SEC to raise up to $7 million in an initial public offering.
The Hong Kong-based company plans to raise $7 million by offering 0.9 million shares at a price range of $7 to $9. At the midpoint of the proposed range, Brand Meditech will command a market cap of $87 million.
It plans to use the proceeds for research and development, business expansion and medical device production.
Company Overview
Brand Meditech is a Cayman Islands holding company that operates primarily through Brand Meditech （Asia） Company Limited in Hong Kong and Niche Medical （Xuzhou） Co., Ltd. in mainland China. The company distributes a broad portfolio of medical devices and medical imaging software sourced from Europe and China, including defibrillators, defibrillator monitors, ventilators, laryngoscopes, accessories, and MRI post?processing software. It also provides installation, maintenance, and training services related to software deployments.
Through Niche Medical, the company is developing proprietary products to complement its distribution business. Commercialized and in limited production are infusion pumps, with anesthesia laryngoscopes slated for production, while portable X?ray systems and automated external defibrillators （AEDs） are advancing through testing and regulatory pathways. The company leverages a development partnership with Germany’s Corscience for AED hardware and ECG analytics. For the fiscal year ended March 31, 2025, Hong Kong-based BM HK generated the vast majority of revenue, while Niche Medical’s contribution reflects the early stage of its commercialization roadmap.
The Hong Kong-based company was founded in 2003 and booked $25 million in revenue for the 12 months ended March 31, 2025. Compared to $26.2 million in the same period last year.
It plans to list on the Nasdaq under the symbol AED. Maxim Group LLC is the sole bookrunner on the deal.
Market Overview
Total addressable market: China’s medical device market was ~$44.8 billion in 2023 （GlobalData） and projected to reach ~$55.67 billion by 2029 （Statista）。
Market growth: Forecast growth rates include >5% through 2025 （GlobalData） and ~7.97% CAGR from 2025–2029 （Statista）。
Market position: Brand Meditech focuses on Hong Kong and mainland China distribution and is expanding proprietary devices via its PRC subsidiary.
Key competitors: Multinational and domestic Chinese device makers and distributors across emergency, imaging, and respiratory categories.
Industry trends: Rising healthcare demand, domestic substitution in high-end segments, innovation approvals, and supportive industrial policies.
Operational Metrics
Customers: Primarily distributors reselling to hospitals and medical institutions in Hong Kong and mainland China; top five customers accounted for 21.5%, 21.2%, 13.3%, 9.1%, and 8.0% of FY2025 revenue
Locations: Headquarters and office in Shatin, Hong Kong; PRC manufacturing site in Xuzhou, Jiangsu
Geographic presence: Majority of revenue from Hong Kong; operations also in mainland China
Partnerships: AED development collaboration with Corscience GmbH & Co. KG （Germany）
Manufacturing capacity: Planned annual capacities—AEDs ~40,000 units, portable X-ray ~4,000 units, infusion pumps ~20,000 units, anesthesia laryngoscopes ~80,000 units
Suppliers: Concentrated vendor base （FY2025 top three suppliers represented ~62.4%, 23.4%, and 13.3% of procurement）
Revenue mix: BM HK contributed ~99.37% of FY2025 revenue; Niche Medical ~0.63%
Financials Highlights
Revenue （current）： $25,488,377 （FY ended March 31, 2025）
Revenue growth: -2.7% YoY （vs. $26,191,243 in FY2024）
Gross profit: $3,992,154 （15.7% margin）
Operating income: $2,467,745
Net income: $1,207,489
Management
Kit Ying Kwan, Chief Executive Officer and Chairwoman – Founder with two decades of medical device distribution experience across Hong Kong and mainland China; leads strategy, partnerships, and operations.
Rui （Kerrie） Zhang, Chief Financial Officer – Former CFO of a U.S.-listed healthcare company; extensive experience in SEC reporting, audits, and financial management.
David Garcia Galvez, Executive Director – Leads product and business development; background in technology and distribution businesses.
Leo De Guzman Vega, Director – General management and strategy experience in medical device trading and technology companies.
James Russell Campbell, Independent Director – Senior operating and management roles in industrial, energy, and equipment sectors.
Daniel S. Szubielski, Independent Director – Commodities and physical asset management professional; experience in acquisitions and portfolio management.
Justin Christopher Evans, Independent Director – Public affairs and strategic communications executive with business development expertise.
IPO Structure
Issuer: Brand Meditech Limited
Filing date: December 11, 2025
Proposed ticker: AED
Exchange: Nasdaq Capital Market
Price range: $7.00–$9.00 per share
Offering size: $7.2 million gross （at $8 midpoint）； up to $8.28 million with over-allotment
Shares offered: 900,000 Class A Ordinary Shares （plus 135,000 share over-allotment option）
Lead underwriters: Maxim Group LLC
Use of proceeds: Approximately $5.7 million net: ~35% R&D, ~30% business expansion, ~20% proprietary medical device production, ~15% working capital and general operations